Perceptive Advisors Lowered Aerie Pharmaceuticals (AERI) Position By $13.20 Million; Gafisa SA (GFA) Shorts Lowered By 15.51%

August 11, 2017 - By sdlfksdklf klsdf

Gafisa SA (NYSE:GFA) had a decrease of 15.51% in short interest. GFA’s SI was 462,100 shares in August as released by FINRA. Its down 15.51% from 546,900 shares previously. With 69,000 avg volume, 7 days are for Gafisa SA (NYSE:GFA)’s short sellers to cover GFA’s short positions. The SI to Gafisa SA’s float is 6.08%. The stock decreased 5.99% or $0.47 on August 11, reaching $7.37. About 125,120 shares traded or 70.97% up from the average. Gafisa SA (ADR) (NYSE:GFA) has declined 42.53% since August 11, 2016 and is downtrending. It has underperformed by 59.23% the S&P500.

Perceptive Advisors Llc decreased Aerie Pharmaceuticals (AERI) stake by 87.71% reported in 2016Q4 SEC filing. Perceptive Advisors Llc sold 356,771 shares as Aerie Pharmaceuticals (AERI)’s stock declined 8.47%. The Perceptive Advisors Llc holds 50,000 shares with $1.89M value, down from 406,771 last quarter. Aerie Pharmaceuticals now has $1.83 billion valuation. The stock decreased 2.14% or $1.1 during the last trading session, reaching $50.35. About 476,944 shares traded or 11.69% up from the average. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 180.20% since August 11, 2016 and is uptrending. It has outperformed by 163.50% the S&P500.

Among 12 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 29 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Friday, October 28 by RBC Capital Markets. Cowen & Co maintained the shares of AERI in report on Wednesday, August 2 with “Buy” rating. Cantor Fitzgerald maintained it with “Buy” rating and $40 target in Thursday, September 17 report. H.C. Wainwright maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) rating on Thursday, July 20. H.C. Wainwright has “Buy” rating and $6900 target. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, September 20. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, September 15 report. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Buy” rating by Canaccord Genuity on Tuesday, December 20. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) has “Strong Buy” rating given on Wednesday, September 14 by Raymond James. Stifel Nicolaus maintained it with “Buy” rating and $40 target in Thursday, September 17 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, September 15.

Since February 14, 2017, it had 1 buy, and 2 selling transactions for $3.02 million activity. The insider Cagle Gerald D. bought $39,900. DUYK GEOFFREY M also sold $1.94 million worth of Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares. 20,000 shares were sold by Foresite Capital Management II – LLC, worth $1.12M.

Perceptive Advisors Llc increased Quotient (NASDAQ:QTNT) stake by 182,692 shares to 2.85 million valued at $13.82M in 2016Q4. It also upped Eiger Biopharmaceuticals stake by 27,759 shares and now owns 157,679 shares. Global Blood Therapeutics was raised too.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>